Parexel cuts revenue forecasts as earnings dip

Related tags Clinical trial United states dollar Parexel

Contract research organisation Parexel posted a 26 per cent hike in first quarter revenues to $263m but still failed to meet its own internal sales targets and saw net profits slide.

Parexel also cut its revenue guidance for the year to $1.1-$1.3bn from $1.22-$1.25bn, blaming the shortfall on currency effects and specifically the strength of the US dollar, as well as “headwinds in the marketplace​,” said CEO Josef von Rickenbach.

We anticipated a slowdown during the summer months, and then expected an acceleration of activity in September as has been typical in the past​,” he added.

Ultimately, however, sales performance for the quarter turned out to be short of target​.”

Parexel’s shares suffered on the back of the results, dropping almost 28 per cent on the day the figures were announced and dipping below $9 for the first time in three years. Since then the shares have staged something of a recovery and were trading at around $10.40 as this article went to press, still well short of the 52-week high of over $36.

Service revenue for the first quarter were was made up of $202.8m in Clinical Research Services (CRS) sales, $30.1m from Parexel Consulting and Medical Communications Services (PCMS), and $30.1 million from the eClinical business Perceptive Informatics, boosted recently from the acquisition of UK-based company ClinPhone.

Backlog was $2.061bn at the end of September, with new business wins of $347m and a contribution of $117m from ClinPhone acquisition. Cancellations amounted to around $83m, and exchange rates pegged the figure back by $116m.

Discussing the impact of the ClinPhone acquisition, von Rickenbach noted that “some short-term acquisition-related challenges prevented us from achieving the expected quarterly results in the Perceptive Informatics business segment.​”

However, we are pleased with the most recent progress of the business unit, and look forward to improved performance as we move ahead​," he added.

Award provides a lift

There was more positive news for Parexel late last week when it was recognized by the Good Clinical Practice Journal (GCPj) as the winner of its Most Innovative Patient Recruitment Strategy Award alongside partner Glenmark Pharmaceuticals.

The firms won the award for an early phase development programme for a diabetes medication. Phase I studies were followed by a 60-patient proof of concept study in at sites in the UK and South Africa.

The approach allowed Glenmark to make a go/no-go decision seven months earlier and the programme was completed 30 per cent faster than is typical during early phase drug development, said the firms.

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more